查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401950

到 2030 年神經刺激的市場預測：按類型、應用和地區分類的全球分析

Neurostimulation Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球神經刺激市場規模為 62.212 億美元，預計到 2030 年將達到 133.29 億美元，預測期內複合年成長率為 11.5%。

使用協調的電或磁脈衝來改變神經系統的活動稱為神經刺激。它用於治療多種神經病變，包括精神疾病、運動障礙和慢性疼痛。此外，神經刺激是一種可逆且可自訂的方式來調節神經迴路並減輕相關症狀，目前正在研究新的應用，並正在最佳化現有技術。

據美國疾病管制與預防美國(CDC) 稱，北美每年估計花費 500 億美元用於治療慢性下背痛。

非侵入性替代方案的增加

由於非侵入性神經刺激方法的發展以及提供非手術方法（例如經顱磁刺激（TMS）和經皮電神經刺激（TENS））的技術進步，這些方法正在獲得認可。該方法正在減少患者的被動性和擴大市場範圍。這項轉變不僅提高了患者的舒適度和安全性，而且還提供了高效、負擔得起的微創解決方案，使我們能夠在塑造神經刺激療法和市場的方向方面發揮關鍵作用。我們正在擴大規模。

高成本

開發、製造和行銷神經刺激設備是一個昂貴的過程，需要先進的技術、廣泛的研究和監管合規性。專用零件、尖端材料和複雜的製造技術都會導致成本高昂。這些高昂的成本給患者和醫療保健提供者在負擔能力和報銷方面帶來了挑戰。因此，高昂的自付費用和缺乏保險覆蓋可能會阻礙神經刺激市場的發展。

技術進步

技術創新推動了封閉回路型或自適應神經刺激系統的發展，電極技術、程式設計能力和設備設計不斷創新，提高了神經刺激治療的準確性、有效性和安全性。此外，無線通訊技術的整合可以更好地病患監測並即時調整神經刺激參數。改善患者治療效果和解決未滿足的醫療需求正在推動整個神經刺激治療市場的發展。

副作用

神經刺激並非對所有神經系統疾病都同樣有效，侵入性手術和植入設備固有的風險（例如感染、設備故障和意外副作用）可能會限制患者的安全、性能和可靠性。此外，不利事件可能會損害產品在市場上的聲譽，引發監管問題和法律問題，並阻礙其普及。結果，神經刺激市場受到阻礙。

COVID-19 的影響

COVID-19 的爆發對神經刺激市場產生了負面影響，擾亂了製造、供應鏈和選擇性醫療程序。對非必要醫療保健服務的限制、患者就診的減少以及醫療資源的轉移正在推遲神經刺激設備並減少患者的就診機會。經濟不確定性也影響投資和研究經費。因此，這些因素都大大阻礙了市場的拓展。

迷走神經刺激設備部分預計在預測期內將是最大的

迷走神經刺激設備部分估計佔最大佔有率。這些植入式設備透過刺激迷走神經來運作，迷走神經向大腦發送電脈衝。技術進步、設備小型化以及對神經生理學理解的加深是有助於提高意識的一些創新。對非藥物治療選擇的需求和神經系統疾病盛行率的增加正在促進 VNS 領域在神經刺激市場的擴張。

帕金森氏症領域預計在預測期內複合年成長率最高

由於使用植入設備來緩解症狀，預計帕金森氏症領域在預測期內的複合年成長率最高。治療帕金森氏症的神經刺激稱為深部腦部刺激 (DBS)，涉及在特定大腦區域植入電極以糾正異常神經活動。 DBS 可改善患者的生活品質、減少藥物依賴性並減少運動症狀。因此，DBS也為神經刺激技術的發展和進步做出了重大貢獻，支持了該領域的擴展。

佔有率最大的地區

由於其醫療基礎設施、報銷政策和法律規範，亞太地區在預測期內佔據了最大的市場佔有率。人口高齡化以及隨之而來的神經退化性疾病的增加導致對神經刺激療法的需求不斷成長。該地區的主要企業包括波士頓科學公司、雅培實驗室、美敦力公司和 Neuronetics, Inc.。該地區的貸款和還款政策以及新技術正在推動市場規模的成長。

複合年成長率最高的地區：

預計歐洲在預測期內的複合年成長率最高。監管機構和國家衛生當局在核准和監管神經刺激設備方面發揮重要作用。治療效果和患者結果的進步包括增強的電極設計、精確定位和先進的程式功能。德國、英國和法國等歐洲國家也為引進神經病變的最尖端科技做出了重大貢獻，並正在推動該地區的成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球神經刺激市場：依類型

  • 薦骨神經刺激器
  • 脊髓刺激設備
  • 迷走神經刺激設備
  • 深層腦部刺激器
  • 其他類型

第6章全球神經刺激市場：依應用分類

  • 聽力損失
  • 尿失禁
  • 疼痛管理
  • 癲癇
  • 帕金森氏症
  • 其他用途

第7章全球神經刺激市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Medtronic
  • LivaNova PLC
  • Abbott
  • Neuronetics
  • Boston Scientific Corporation
  • Nevro Corp
  • LABORIE
  • Johnson & Johnson Services
  • NeuroPace, Inc.
  • Synapse Biomedical Inc
  • NeuroSigma, Inc
  • Modulus, Inc
  • Biegler GmbH
Product Code: SMRC24470

According to Stratistics MRC, the Global Neurostimulation Market is accounted for $6,221.2 million in 2023 and is expected to reach $13,329.0 million by 2030 growing at a CAGR of 11.5% during the forecast period. The use of regulated electrical or magnetic impulses to alter the nervous system's activity is known as neurostimulation. It is used to treat various neurological disorders such as psychiatric disorders, movement disorders, and chronic pain. Furthermore, neurostimulation is a potentially reversible and customizable method of modulating neural circuitry and relieving symptoms associated, with ongoing research exploring new applications and optimizing existing technologies.

According to Centers for Disease Control and Prevention (CDC), an estimated USD 50 billion are spent each year for treatment of chronic lower back pain in North America.

Market Dynamics:

Driver:

Increase in non-invasive alternatives

The development of non-invasive neurostimulation methods and their increasing acceptance as a result of technological advancements like transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS) which offer non-surgical approaches, reducing patient reluctance and expanding the market reach. This shift not only improve patient comfort and safety but also provide efficient, affordable, and minimally invasive solutions which place them in a position to play a significant role in influencing the direction of neurostimulation therapy, which are driving the market size.

Restraint:

High cost

Neurostimulation device development, manufacture, and distribution are expensive processes that require sophisticated technology, a great deal of research, and adherence to regulations. Specialized parts, cutting-edge materials, and complex manufacturing techniques all contribute to the higher expenses. In terms of affordability and reimbursement, these exorbitant cost present difficulties for patients and healthcare providers. Therefore, high out-of-pocket costs and a lack of insurance coverage may impede neurostimulation market.

Opportunity:

Technological advancements

Technological innovations have facilitated the development of closed-loop or adaptive neurostimulation systems with constant innovations including electrode technologies, programming capabilities, and device design which improves the accuracy, effectiveness, and safety of neurostimulation treatments. In addition, integration of wireless communication technologies enables better patient monitoring and real-time adjustments to neurostimulation parameters. By improving patient outcomes and addressing unmet medical needs overall propels the neurostimulation market.

Threat:

Side effects

Neurostimulation may not be equally effective for all neurological conditions which effects patient safety and confidence by the inherent risks associated with invasive procedures and implantable devices, which include infection, malfunctioning of the device, and unintended side effects. Moreover, adverse events can damage a product's reputation in the market and prevent its widespread adoption by giving rise to regulatory worries and legal issues. Thus, consequently hinder the neurostimulation market.

COVID-19 Impact

The COVID-19 pandemic has negatively impacted the neurostimulation market, causing disruptions in manufacturing, supply chains, and elective medical procedures. Restrictions on non-essential healthcare services, reduced patient visits, and diverted healthcare resources have led to delays in neurostimulation device implantations and decreased patient access. Economic uncertainties have also affected investment and research funding. Therefore, these factors significantly impede market expansion.

The vagus nerve stimulators segment is expected to be the largest during the forecast period

The vagus nerve stimulators segment is estimated to hold the largest share. These implantable devices stimulate the vagus nerve, which operates by sending electrical impulses to the brain. Technological advancements, miniaturization of devices, and improved understanding of neurophysiology are some of the innovations contributing awareness. The demand for non-pharmacological treatment options and the increasing prevalence of neurological disorders contribute to the expansion of the VNS segment in the Neurostimulation market.

The parkinson's disease segment is expected to have the highest CAGR during the forecast period

The parkinson's disease segment is anticipated to have the highest CAGR during the forecast period due to reducing symptoms by using implantable devices. Neurostimulation for Parkinson's disease is called deep brain stimulation (DBS), which involves implanting electrodes in particular brain areas to modify aberrant neural activity. The patients' quality of life is improved, medication dependence is decreased, and motor symptoms are reduced with DBS. Hence, it also makes a substantial contribution to the development and advancement of neurostimulation technologies which are propelling this segment expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to evaluations of the healthcare infrastructure, reimbursement policies, and regulatory frameworks. The aging population and the subsequent increase in neurodegenerative diseases contribute to the expanding demand for neurostimulation therapies. The region is home to major key players such as Boston Scientific Corporation, Abbott Laboratories, Medtronic plc and Neuronetics, Inc. The region's financing and reimbursement policies and new technologies is driving the market size.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period. Regulatory bodies and national health authorities play a crucial role in approving and regulating neurostimulation devices. Advancements in treatment efficacy and patient outcomes include enhanced electrode designs, precise targeting, and advanced programming capabilities. Countries within Europe, including Germany, the United Kingdom, France, and others, also contribute significantly to the adoption of cutting-edge technologies for neurological disorders which thereby driving region growth.

Key players in the market:

Some of the key players in the Neurostimulation Market include Medtronic, LivaNa PLC, Abbott, Neuronetics, Boston Scientific Corporation, Nevro Corp, Laborie, Johnson & Johnson Services, NeuroPace, Inc., Synapse Biomedical Inc, NeuroSigma, Inc, Modulus, Inc and Biegler GmbH.

Key Developments:

In October 2023, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems for the treatment of painful diabetic peripheral neuropathy (DPN), a complication of diabetes that can affect the lower extremities of the body.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In August 2023, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System.

In June 2023, the American Diabetes Association® (ADA) and Abbott announced a collaboration aimed at better understanding how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.

Types Covered:

  • Sacral Nerve Stimulators
  • Spinal Cord Stimulators
  • Vagus Nerve Stimulators
  • Deep Brain Stimulators
  • Other Types

Applications Covered:

  • Hearing Loss
  • Urinary Incontinence
  • Pain Management
  • Epilepsy
  • Parkinson's disease
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurostimulation Market, By Type

  • 5.1 Introduction
  • 5.2 Sacral Nerve Stimulators
  • 5.3 Spinal Cord Stimulators
  • 5.4 Vagus Nerve Stimulators
  • 5.5 Deep Brain Stimulators
  • 5.6 Other Types

6 Global Neurostimulation Market, By Application

  • 6.1 Introduction
  • 6.2 Hearing Loss
  • 6.3 Urinary Incontinence
  • 6.4 Pain Management
  • 6.5 Epilepsy
  • 6.6 Parkinson's disease
  • 6.7 Other Applications

7 Global Neurostimulation Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Medtronic
  • 9.2 LivaNova PLC
  • 9.3 Abbott
  • 9.4 Neuronetics
  • 9.5 Boston Scientific Corporation
  • 9.6 Nevro Corp
  • 9.7 LABORIE
  • 9.8 Johnson & Johnson Services
  • 9.9 NeuroPace, Inc.
  • 9.10 Synapse Biomedical Inc
  • 9.11 NeuroSigma, Inc
  • 9.12 Modulus, Inc
  • 9.13 Biegler GmbH

List of Tables

  • Table 1 Global Neurostimulation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 4 Global Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 5 Global Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 6 Global Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 7 Global Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 9 Global Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 10 Global Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 11 Global Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 12 Global Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 13 Global Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 14 Global Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 15 North America Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 17 North America Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 18 North America Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 19 North America Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 20 North America Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 21 North America Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 22 North America Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 North America Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 24 North America Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 25 North America Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 26 North America Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 27 North America Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 28 North America Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Europe Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 31 Europe Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 32 Europe Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 33 Europe Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 34 Europe Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 35 Europe Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 36 Europe Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 Europe Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 38 Europe Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 39 Europe Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 40 Europe Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 41 Europe Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 42 Europe Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Asia Pacific Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 46 Asia Pacific Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 47 Asia Pacific Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 48 Asia Pacific Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 49 Asia Pacific Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 50 Asia Pacific Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 51 Asia Pacific Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 52 Asia Pacific Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 53 Asia Pacific Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 54 Asia Pacific Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 55 Asia Pacific Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 56 Asia Pacific Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 57 South America Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 59 South America Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 60 South America Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 61 South America Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 62 South America Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 63 South America Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 64 South America Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 65 South America Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 66 South America Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 67 South America Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 68 South America Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 69 South America Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 70 South America Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 71 Middle East & Africa Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 74 Middle East & Africa Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 75 Middle East & Africa Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 76 Middle East & Africa Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 77 Middle East & Africa Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Middle East & Africa Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 Middle East & Africa Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 80 Middle East & Africa Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 81 Middle East & Africa Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 82 Middle East & Africa Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 83 Middle East & Africa Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 84 Middle East & Africa Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)